Financial Performance - The company's revenue for Q1 2022 was ¥72,887,112.31, a decrease of 40.23% compared to ¥121,941,030.65 in the same period last year[3] - Net profit attributable to shareholders was ¥8,912,462.89, down 59.10% from ¥21,792,577.65 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,334,047.77, a significant decline of 92.62% from ¥18,086,835.01 in the previous year[3] - Total operating revenue for the current period was ¥72,887,112.31, a decrease of 40.2% compared to ¥121,941,030.65 in the previous period[16] - Net profit for the current period was ¥8,524,544.62, a decline of 59.3% from ¥20,988,719.93 in the previous period[18] - Operating profit decreased to ¥9,381,414.07, down 60.5% from ¥23,779,164.45[17] - Basic and diluted earnings per share were both ¥0.11, compared to ¥0.36 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥15,632,963.13, compared to a positive ¥21,967,398.51 in the same period last year, marking a 171.16% decrease[3] - Cash flow from operating activities showed a net outflow of ¥15,632,963.13, contrasting with a net inflow of ¥21,967,398.51 in the previous period[21] - Cash and cash equivalents at the end of the period were ¥433,237,666.85, down from ¥119,285,563.08 at the end of the previous period[21] - The company's cash and cash equivalents decreased from ¥610,930,333.64 at the beginning of the year to ¥563,769,166.85 at the end of the reporting period, a decline of approximately 7.7%[12] - Investment activities resulted in a net cash outflow of ¥31,499,953.66, compared to a smaller outflow of ¥1,864,043.94 previously[21] - Financing activities generated a net cash outflow of ¥400,000.00, compared to an outflow of ¥5,309,736.10 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥842,026,922.74, a decrease of 1.10% from ¥851,423,622.82 at the end of the previous year[3] - Total assets decreased from ¥851,423,622.82 to ¥842,026,922.74, a decline of about 1.7%[15] - Total liabilities decreased from ¥62,789,771.85 to ¥45,268,527.15, a reduction of approximately 28.1%[14] - The company's total equity increased from ¥788,633,850.97 to ¥796,758,395.59, an increase of about 1.4%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,069, with no preferred shareholders[9] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of shares, totaling 46,677,966 shares, with 2,100,000 shares pledged[9] - The number of shares held by the top ten shareholders reflects a concentration of ownership, with the top shareholder alone holding over 58%[9] Operational Challenges - The company's core product, sodium acetate injection, experienced a sales decline due to local medical insurance adjustments, COVID-19 impacts, and a 10% decrease in average selling price[8] - The company reported a significant increase in credit impairment losses of 599.27%, amounting to ¥1,220,031.51, due to a reduction in bad debt provisions[8] - Other income increased by 103.99% to ¥8,327,479.77, primarily due to an increase in government subsidies received[8] Inventory and Receivables - Accounts receivable decreased from ¥98,290,746.40 to ¥69,758,683.26, representing a reduction of about 29%[12] - Inventory increased from ¥9,824,013.58 to ¥12,041,838.71, marking an increase of approximately 22.4%[13] - Accounts receivable financing rose by 81.94% to ¥3,703,173.46, attributed to an increase in received bank acceptance bills[7] Audit and Reporting - The company did not conduct an audit for the first quarter report[22] - The company has not disclosed any new product developments or market expansion strategies in the current report[11]
多瑞医药(301075) - 2022 Q1 - 季度财报